THE RELATIONSHIP OF P53 PROTEIN AND LYMPH-NODE METASTASES IN INVASIVE BREAST-CANCER

被引：8

作者：

NOGUCHI, M

KITAGAWA, H

KINOSHITA, K

THOMAS, M

MIYAZAKI, I

SAITO, Y

MIZUKAMI, Y

NONOMURA, A

MICHIGISHI, T

NAKAMURA, S

机构：

[1] The Operation Center, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

[2] Department of Surgery II, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

[3] Department of Surger, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

[4] Department of Pathology, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

[5] Department of Nuclear Medicine, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

[6] Deparment of Medicine III, Kanazawa University Hospital, School of Medicine, Kanazawa, 920, Takara-machi

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1994年 / 24卷 / 06期

关键词：

P53; PROTEIN; BREAST CANCER; LYMPH NODE METASTASIS;

D O I：

10.1007/BF01884570

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The p53 expression in invasive breast cancers from 106 patients was correlated with clinicopathological variables to ascertain its usefulness for estimating prognosis. The p53 expression was significantly associated with the number of axillary lymph node metastases and the presence of internal mammary lymph node metastases; however, it was not associated with age, menopausal status, histologic type, or tumor size. Although p53 expression was a significant prognostic factor according to univariate analysis, it did not appear to be an independent prognostic factor according to multivariate analysis. Thus, the prognostic power of p53 expression is likely to be weak and therefore probably of limited clinical value. Nevertheless, the number of patients in our study was small, and we believe that an investigation of a larger series of patients is indicated.

引用

页码：512 / 517

页数：6

共 32 条

[21]

Levine A.J., Momand J., Finlay C.A., The p53 tumour suppressor gene, Nature, 351, pp. 453-456, (1991)

[22]

Milner J., Medcalf E.A., Cook A.C., Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes, Mol Cell Biol, 11, pp. 12-19, (1991)

[23]

Varley J.M., Brammar W.J., Lane D.P., Swallow E.S., Dolan C., Walker R.A., Loss of chromosome l7p13 sequences and mutation of p53 in human breast carcinomas, Oncogene, 6, pp. 413-421, (1991)

[24]

Spandidos D.A., Karaiossifidi H., Malliri A., Linardopoulos S., Vassilaros S., Tsikkinis A., Field J.K., Expression of Ras Rbl and p53 proteins in human breast cancer, Anticancer Res, 12, pp. 81-90, (1992)

[25]

Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D., p53 expression in breast cancer, Int J Cancer, 41, pp. 178-183, (1988)

[26]

Cattoretti G., Andreola S., Clemente C., D'Amato L., Rilke F., Vimentin and p53 expression on epidermal growth factor receptor-positive oestrogen-negative breast carcinomas, Br J Cancer, 57, pp. 353-357, (1988)

[27]

Thompson A.M., Steel C.M., Chetty U., Hawkins R.A., Miller W.R., Carter D.C., Forrest A.P.M., Evans H.J., p53 gene mRNA expression and chromosome 17p allele loss in breast cancer, Br J Cancer, 61, pp. 74-78, (1990)

[28]

Koutselini H., Malliri A., Field J.K., Spandidos D.A., p53 expression in cytological specimens from benign and malignant breast lesions, Anticancer Res, 11, pp. 1415-1420, (1991)

[29]

Noguchi M., Kitagawa H., Kinoshita K., Miyazaki I., Saito Y., Mizukami Y., Prognostic significance of p53 and c- erbB- 2 expression in operable breast cancer, Int J Oncol, 2, pp. 587-591, (1993)

[30]

McGuire W.L., Tandon A.K., Allred D.C., Chamness G.C., Clark G.M., How to use prognostic factors in axillary node-negative breast cancer patients, J Natl Cancer Inst, 82, pp. 1006-1015, (1990)

← 1 2 3 4 →